Connetics plans new trial for Extina
Seven months after receiving a not approvable letter from the FDA for Extina -- an experimental skin treatment -- Connetics says it will begin a late-stage trial in the third quarter to prove it works. Extina was developed for an inflammatory skin disease called seborrhic dermatitis. Connetics says its new schedule will put it on track to file another NDA on the treatment in the second half of 2006.
- read this story from Forbes for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
